245 related articles for article (PubMed ID: 8917560)
21. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
[TBL] [Abstract][Full Text] [Related]
22. Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis.
Julias JG; Boyer PL; McWilliams MJ; Alvord WG; Hughes SH
Virology; 2004 Apr; 322(1):13-21. PubMed ID: 15063112
[TBL] [Abstract][Full Text] [Related]
23. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.
Sarafianos SG; Das K; Clark AD; Ding J; Boyer PL; Hughes SH; Arnold E
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10027-32. PubMed ID: 10468556
[TBL] [Abstract][Full Text] [Related]
24. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
[TBL] [Abstract][Full Text] [Related]
25. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
[TBL] [Abstract][Full Text] [Related]
27. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
Balzarini J; Pelemans H; Esnouf R; De Clercq E
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):255-60. PubMed ID: 9491916
[TBL] [Abstract][Full Text] [Related]
28. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
29. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
[TBL] [Abstract][Full Text] [Related]
30. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
Pelemans H; Esnouf RM; Jonckheere H; De Clercq E; Balzarini J
J Biol Chem; 1998 Dec; 273(51):34234-9. PubMed ID: 9852086
[TBL] [Abstract][Full Text] [Related]
32. Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
Balzarini J; Wedgwood O; Kruining J; Pelemans H; Heijtink R; De Clercq E; McGuigan C
Biochem Biophys Res Commun; 1996 Aug; 225(2):363-9. PubMed ID: 8753770
[TBL] [Abstract][Full Text] [Related]
33. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
Balzarini J
Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
[TBL] [Abstract][Full Text] [Related]
34. Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
Boyer PL; Melody K; Smith SJ; Dunn LL; Kline C; Fischer DK; Dwivedi R; Clark P; Hughes SH; Ambrose Z
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894467
[TBL] [Abstract][Full Text] [Related]
35. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
36. Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.
Hoffmann D; Garcia AD; Harrigan PR; Johnston IC; Nakasone T; García-Lerma JG; Heneine W
PLoS One; 2011; 6(7):e22019. PubMed ID: 21799767
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
39. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
Mansky LM; Pearl DK; Gajary LC
J Virol; 2002 Sep; 76(18):9253-9. PubMed ID: 12186909
[TBL] [Abstract][Full Text] [Related]
40. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
Miller MD; Anton KE; Mulato AS; Lamy PD; Cherrington JM
J Infect Dis; 1999 Jan; 179(1):92-100. PubMed ID: 9841827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]